In vivo pharmacology of aprosulate, a new synthetic polyanion with anticoagulant activity.
The in vivo effects of a new synthetic inhibitor of blood coagulation, aprosulate sodium, were investigated. Intravenous bolus injection of aprosulate or standard heparin in rats produced an immediate prolongation of the APTT which were characterized by a moderate dose-dependency and long-lasting duration when compared with those of standard heparin. Standard heparin inhibited plasma factor Xa activity, but aprosulate did not even at the highest dose used. Both agents inhibited thrombus formation in a dose-dependent manner in an arterio-venous shunt model. At antithrombotic doses, standard heparin prolonged the bleeding time measured by the tail transection method, but aprosulate did not. The present results suggest that aprosulate has promising in vivo profile as an anticoagulant and antithrombotic agent.
Sugidachi
A
A
Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Asai
F
F
Koike
H
H
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D004187:Disaccharides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006487:Hemostasis / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D008297:Male; D010314:Partial Thromboplastin Time; D000071228:Polyelectrolytes; D011108:Polymers; D051381:Rats; D017207:Rats, Sprague-Dawley
D000925:Anticoagulants; D004187:Disaccharides; D005343:Fibrinolytic Agents; D006493:Heparin; D000071228:Polyelectrolytes; D011108:Polymers; C069690:aprosulate